{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T20:35:22Z","timestamp":1789763722069,"version":"4.0.1"},"reference-count":51,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2020,3,4]],"date-time":"2020-03-04T00:00:00Z","timestamp":1583280000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2020,3,4]],"date-time":"2020-03-04T00:00:00Z","timestamp":1583280000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Acta Pharmacol Sin"],"published-print":{"date-parts":[[2020,9]]},"DOI":"10.1038\/s41401-020-0370-1","type":"journal-article","created":{"date-parts":[[2020,3,4]],"date-time":"2020-03-04T14:03:14Z","timestamp":1583330594000},"page":"1158-1166","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["Ritanserin blocks CaV1.2 channels in rat artery smooth muscles: electrophysiological, functional, and computational studies"],"prefix":"10.1038","volume":"41","author":[{"given":"Fabio","family":"Fusi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alfonso","family":"Trezza","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giampietro","family":"Sgaragli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ottavia","family":"Spiga","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simona","family":"Saponara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sergio","family":"Bova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,3,4]]},"reference":[{"key":"370_CR1","first-page":"600","volume":"27","author":"JE Leysen","year":"1985","unstructured":"Leysen JE, Gommeren W, Van Gompel P, Wynants J, Janssen PF, Laduron PM. Receptor-binding properties in vitro and in vivo of ritanserin: a very potent and long acting serotonin-S2 antagonist. Mol Pharmacol 1985;27:600\u201311.","journal-title":"Mol Pharmacol"},{"key":"370_CR2","unstructured":"https:\/\/www.guidetopharmacology.org\/GRAC\/LigandDisplayForward?tab=biology&ligandId=97. Accessed 9 Mar 2019."},{"key":"370_CR3","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1002\/da.22236","volume":"31","author":"L Kriston","year":"2014","unstructured":"Kriston L, von Wolff A, Westphal A, H\u00f6lzel LP, H\u00e4rter M. Efficacy and acceptability of acute treatments for persistent depressive disorder: a network meta-analysis. Depress Anxiety 2014;31:621\u201330.","journal-title":"Depress Anxiety"},{"key":"370_CR4","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1192\/bjp.bp.109.067710","volume":"197","author":"SP Singh","year":"2010","unstructured":"Singh SP, Singh V, Kar N, Chan K. Efficacy of antidepressants in treating the negative symptoms of chronic schizophrenia: meta-analysis [published correction appears in Br J Psychiatry. 2011;198:159]. Br J Psychiatry. 2010;197:174\u20139.","journal-title":"Br J Psychiatry"},{"key":"370_CR5","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1016\/S0376-8716(00)00140-X","volume":"61","author":"JW Cornish","year":"2001","unstructured":"Cornish JW, Maany I, Fudala PJ, Ehrman RN, Robbins SJ, O\u2019Brien CP. A randomized, double-blind, placebo-controlled study of ritanserin pharmacotherapy for cocaine dependence. Drug Alcohol Depend. 2001;61:183\u20139.","journal-title":"Drug Alcohol Depend"},{"key":"370_CR6","doi-asserted-by":"crossref","first-page":"88","DOI":"10.3181\/00379727-199-43334","volume":"199","author":"K Wu","year":"1992","unstructured":"Wu K, Hunter TL, Proakis AG. Effects of ritanserin on transmembrane action potentials in canine purkinje fibres. Proc Soc Exp Biol Med. 1992;199:88\u201392.","journal-title":"Proc Soc Exp Biol Med"},{"key":"370_CR7","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/j.bcp.2016.10.011","volume":"123","author":"S Boroda","year":"2017","unstructured":"Boroda S, Niccum M, Raje V, Purow BV, Harris TE. Dual activities of ritanserin and R59022 as DGKa inhibitors and serotonin receptor antagonists. Biochem Pharmacol. 2017;123:29\u201339.","journal-title":"Biochem Pharmacol"},{"key":"370_CR8","doi-asserted-by":"crossref","first-page":"965","DOI":"10.1007\/s00262-018-2154-8","volume":"67","author":"J Arranz-Nicol\u00e1s","year":"2018","unstructured":"Arranz-Nicol\u00e1s J, Ogando J, Soutar D, Arcos-P\u00e9rez R, Meraviglia-Crivelli D, Ma\u00f1es S, et al. Diacylglycerol kinase \u03b1 inactivation is an integral component of the costimulatory pathway that amplifies TCR signals. Cancer Immunol Immunother. 2018;67:965\u201398.","journal-title":"Cancer Immunol Immunother"},{"key":"370_CR9","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1093\/neuonc\/nox119","volume":"20","author":"I Olmez","year":"2018","unstructured":"Olmez I, Love S, Xiao A, Manigat L, Randolph P, McKenna BD, et al. Targeting the mesenchymal subtype in glioblastoma and other cancers via inhibition of diacylglycerol kinase alpha. Neuro Oncol. 2018;20:192\u2013202.","journal-title":"Neuro Oncol"},{"key":"370_CR10","doi-asserted-by":"crossref","first-page":"870","DOI":"10.1016\/j.chembiol.2017.06.007","volume":"24","author":"CE Franks","year":"2017","unstructured":"Franks CE, Campbell ST, Purow BW, Harris TE, Hsu KL. The ligand binding landscape of diacylglycerol kinases. Cell Chem Biol. 2017;24:870\u201380.","journal-title":"Cell Chem Biol"},{"key":"370_CR11","doi-asserted-by":"crossref","first-page":"1246","DOI":"10.1124\/mol.118.113001","volume":"94","author":"ST Campbell","year":"2018","unstructured":"Campbell ST, Franks CE, Borne AL, Shin M, Zhang L, Hsu KL. Chemoproteomic discovery of a ritanserin-targeted kinase network mediating apoptotic cell death of lung tumor cells. Mol Pharmacol. 2018;94:1246\u201355.","journal-title":"Mol Pharmacol"},{"key":"370_CR12","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1002\/ddr.430080122","volume":"8","author":"JM Van Nueten","year":"1986","unstructured":"Van Nueten JM, Schuurkes JAJ, De Ridder WJE, Kuyps JJMD, Janssens WJ. Comparative pharmacological profile of ritanserin and ketanserin. Drug Dev Res. 1986;8:187\u201395.","journal-title":"Drug Dev Res"},{"key":"370_CR13","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1007\/BF00165548","volume":"335","author":"M Frenken","year":"1987","unstructured":"Frenken M, Kaumann AJ. Allosteric properties of the 5-HT2 receptor system of the rat tail artery. Ritanserin and methysergide are not competitive 5-HT2 receptor antagonists but allosteric modulators. Naunyn Schmiedebergs Arch Pharmacol. 1987;335:359\u201366.","journal-title":"Naunyn Schmiedebergs Arch Pharmacol"},{"key":"370_CR14","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1111\/j.1476-5381.1986.tb11128.x","volume":"89","author":"S Conolan","year":"1986","unstructured":"Conolan S, Quinn MJ, Taylor DA. In vivo and in vitro activity of selective 5-hydroxytryptamine2 receptor antagonists. Br J Pharmacol. 1986;89:129\u201335.","journal-title":"Br J Pharmacol"},{"key":"370_CR15","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1097\/00005344-199504000-00014","volume":"25","author":"EO Okoro","year":"1995","unstructured":"Okoro EO, Marwood JF, Stokes GS. The interaction between Ca2+, verapamil and ketanserin in rat tail artery aorta. J Cardiovasc Pharmacol. 1995;25:603\u201310.","journal-title":"J Cardiovasc Pharmacol"},{"key":"370_CR16","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1111\/j.1440-1681.1997.tb01780.x","volume":"24","author":"EO Okoro","year":"1997","unstructured":"Okoro EO, Marwood JF. Effects of 5-HT2 receptor antagonists on responses to potassium depolarization, in rat isolated aorta. Clin Exp Pharmacol Physiol. 1997;24:34\u20139.","journal-title":"Clin Exp Pharmacol Physiol"},{"key":"370_CR17","doi-asserted-by":"crossref","first-page":"953","DOI":"10.1211\/0022357991773221","volume":"51","author":"EO Okoro","year":"1999","unstructured":"Okoro EO. Overlap in the pharmacology of L-type Ca2+-channel blockers and 5-HT2 receptor antagonists in rat aorta. J Pharm Pharmacol. 1999;51:953\u20137.","journal-title":"J Pharm Pharmacol"},{"key":"370_CR18","first-page":"504","volume":"38","author":"S Kumagai","year":"1998","unstructured":"Kumagai S, Morinobu A, Ozaki S, Nakao K, Ishida H. Sarpogrelate hydrochloride for Raynaud\u2019s phenomenon of patients with collagen diseases. Ryumachi. 1998;38:504\u201310.","journal-title":"Ryumachi"},{"key":"370_CR19","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1111\/j.1346-8138.2011.01432.x","volume":"39","author":"T Yoshimasu","year":"2012","unstructured":"Yoshimasu T, Ikeda T, Uede K, Kanazawa N, Furukawa F. Effects of sarpogrelate hydrochloride on skin ulcers and quality of life in patients with systemic sclerosis. J Dermatol. 2012;39:536\u201340.","journal-title":"J Dermatol"},{"key":"370_CR20","first-page":"A483","volume":"11","author":"T Ogawa","year":"2008","unstructured":"Ogawa T, Ogura T, Hirata A, Hayashi N, Izumi Y, Morita S, et al. Sarpogrelate hydrochloride therapy for Raynaud\u2019s phenomenon in patients with systemic sclerosis. Int J Rheum Dis. 2008;11:A483.","journal-title":"Int J Rheum Dis"},{"key":"370_CR21","first-page":"CD000467","volume":"12","author":"F Rirash","year":"2017","unstructured":"Rirash F, Tingey PC, Harding SE, Maxwell LJ, Tanjong Ghogomu E, Wells GA, et al. Calcium channel blockers for primary and secondary Raynaud\u2019s phenomenon. Cochrane Database Syst Rev. 2017;12:CD000467.","journal-title":"Cochrane Database Syst Rev"},{"key":"370_CR22","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1124\/pr.114.009654","volume":"67","author":"GW Zamponi","year":"2015","unstructured":"Zamponi GW, Striessnig J, Koschak A, Dolphin AC. The physiology, pathology, and pharmacology of voltage-gated calcium channels and their future therapeutic potential. Pharmacol Rev. 2015;67:821\u201370.","journal-title":"Pharmacol Rev"},{"key":"370_CR23","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1124\/jpet.109.161265","volume":"332","author":"F Fusi","year":"2010","unstructured":"Fusi F, Cavalli M, Mulholland D, Crouch NR, Coombes P, Dawson G, et al. Cardamonin is a bifunctional vasodilator that inhibits CaV1.2 current and stimulates KCa1.1 current in rat tail artery myocytes. J Pharmacol Exp Ther. 2010;332:531\u201340.","journal-title":"J Pharmacol Exp Ther"},{"key":"370_CR24","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1111\/apha.12282","volume":"211","author":"P Mugnai","year":"2014","unstructured":"Mugnai P, Durante M, Sgaragli G, Saponara S, Paliuri G, Bova S, et al. L-type Ca2+ channel current characteristics are preserved in rat tail artery myocytes after one-day storage. Acta Physiol. 2014;211:334\u201345.","journal-title":"Acta Physiol"},{"key":"370_CR25","doi-asserted-by":"crossref","first-page":"790","DOI":"10.1124\/jpet.104.080135","volume":"313","author":"F Fusi","year":"2005","unstructured":"Fusi F, Sgaragli G, Saponara S. Mechanism of myricetin stimulation of vascular L-type Ca2+ current. J Pharmacol Exp Ther. 2005;313:790\u20137.","journal-title":"J Pharmacol Exp Ther"},{"key":"370_CR26","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1046\/j.1365-201X.2001.00907.x","volume":"173","author":"GV Petkov","year":"2001","unstructured":"Petkov GV, Fusi F, Saponara S, Gagov H, Sgaragli GP, Boev KK. Characterization of voltage-gated calcium currents in freshly isolated smooth muscle cells from rat tail main artery. Acta Physiol Scand. 2001;173:257\u201365.","journal-title":"Acta Physiol Scand"},{"key":"370_CR27","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.33549\/physiolres.932000","volume":"59","author":"M Karma\u017e\u00ednov\u00e1","year":"2010","unstructured":"Karma\u017e\u00ednov\u00e1 M, Lacinov\u00e1 \u013d. Measurement of cellular excitability by whole cell patch clamp technique. Physiol Res. 2010;59:S1\u20137.","journal-title":"Physiol Res"},{"key":"370_CR28","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1111\/j.1476-5381.1980.tb07892.x","volume":"69","author":"BM Altura","year":"1980","unstructured":"Altura BM, Altura BT, Carella A, Turlapaty PD. Adverse effects of artificial buffers on contractile responses of arterial and venous smooth muscle. Br J Pharmacol. 1980;69:207\u201314.","journal-title":"Br J Pharmacol"},{"key":"370_CR29","doi-asserted-by":"crossref","first-page":"1041","DOI":"10.1111\/j.1476-5381.1996.tb16694.x","volume":"117","author":"S Bova","year":"1996","unstructured":"Bova S, Trevisi L, Debetto P, Cima L, Furnari M, Luciani S, et al. Vasorelaxant properties of norbormide, a selective vasoconstrictor agent for the rat microvasculature. Br J Pharmacol. 1996;117:1041\u20136.","journal-title":"Br J Pharmacol"},{"key":"370_CR30","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1007\/PL00005278","volume":"358","author":"M Magnon","year":"1998","unstructured":"Magnon M, Calderone V, Floch A, Cavero I. Influence of depolarization on vasorelaxant potency and efficacy of Ca2+ entry blockers, K+ channel openers, nitrate derivatives, salbutamol and papaverine in rat aortic rings. Naunyn Schmiedeberg\u2019s Arch Pharmacol. 1998;358:452\u201363.","journal-title":"Naunyn Schmiedeberg\u2019s Arch Pharmacol"},{"key":"370_CR31","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/j.vph.2015.11.041","volume":"76","author":"F Fusi","year":"2016","unstructured":"Fusi F, Manetti F, Durante M, Sgaragli G, Saponara S. The vasodilator papaverine stimulates L-type Ca2+ current in rat tail artery myocytes via a PKA-dependent mechanism. Vasc Pharmacol. 2016;76:53\u201361.","journal-title":"Vasc Pharmacol"},{"key":"370_CR32","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1186\/s13321-016-0139-1","volume":"8","author":"MR Koebel","year":"2016","unstructured":"Koebel MR, Schmadeke G, Posner RG, Sirimulla S. AutoDock VinaXB: implementation of XBSF, new empirical halogen bond scoring function, into AutoDock Vina. J Cheminform. 2016;8:27.","journal-title":"J Cheminform"},{"key":"370_CR33","doi-asserted-by":"crossref","first-page":"D1202","DOI":"10.1093\/nar\/gkv951","volume":"44","author":"S Kim","year":"2016","unstructured":"Kim S, Thiessen PA, Bolton EE, Chen J, Fu G, Gindulyte A, et al. PubChem substance and compound databases. Nucleic Acids Res. 2016;44:D1202\u201313.","journal-title":"Nucleic Acids Res"},{"key":"370_CR34","doi-asserted-by":"crossref","first-page":"2785","DOI":"10.1002\/jcc.21256","volume":"16","author":"GM Morris","year":"2009","unstructured":"Morris GM, Huey R, Lindstrom W, Sanner MF, Belew RK, Goodsell DS, et al. Autodock4 and AutoDockTools4: automated docking with selective receptor flexibility. J Comput Chem. 2009;16:2785\u201391.","journal-title":"J Comput Chem"},{"key":"370_CR35","doi-asserted-by":"crossref","first-page":"W443","DOI":"10.1093\/nar\/gkv315","volume":"43","author":"S Salentin","year":"2015","unstructured":"Salentin S, Schreiber S, Haupt VJ, Adasme MF, Schroeder M. PLIP: fully automated protein\u2013ligand interaction profiler. Nucleic Acids Res. 2015;43:W443\u20137.","journal-title":"Nucleic Acids Res"},{"key":"370_CR36","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1085\/jgp.81.5.613","volume":"81","author":"BP Bean","year":"1983","unstructured":"Bean BP, Cohen CJ, Tsien RW. Lidocaine block of cardiac sodium channels. J Gen Physiol. 1983;81:613\u201342.","journal-title":"J Gen Physiol"},{"key":"370_CR37","doi-asserted-by":"crossref","first-page":"1400","DOI":"10.1084\/jem.148.5.1400","volume":"148","author":"HE Ives","year":"1978","unstructured":"Ives HE, Schultz GS, Galardy RE, Jamieson JD. Preparation of functional smooth muscle cells from the rabbit aorta. J Exp Med. 1978;148:1400\u201313.","journal-title":"J Exp Med"},{"key":"370_CR38","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1111\/bph.13369","volume":"173","author":"S Saponara","year":"2016","unstructured":"Saponara S, Durante M, Spiga O, Mugnai P, Sgaragli G, Huong TT, et al. Functional, electrophysiological and molecular docking analysis of the modulation of CaV1.2 channels in rat vascular myocytes by murrayafoline A. Br J Pharmacol. 2016;173:292\u2013304.","journal-title":"Br J Pharmacol"},{"key":"370_CR39","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1146\/annurev.pharmtox.37.1.361","volume":"37","author":"GH Hockerman","year":"1997","unstructured":"Hockerman GH, Peterson BZ, Johnson BD, Catterall WA. Molecular determinants of drug binding and action on L-type calcium channels. Annu Rev Pharmacol Toxicol. 1997;37:361\u201396.","journal-title":"Annu Rev Pharmacol Toxicol"},{"key":"370_CR40","doi-asserted-by":"crossref","first-page":"1819","DOI":"10.1038\/sj.bjp.0704631","volume":"135","author":"S Saponara","year":"2002","unstructured":"Saponara S, Sgaragli G, Fusi F. Quercetin as a novel activator of L-type Ca2+ channels in rat tail artery smooth muscle cells. Br J Pharmacol. 2002;135:1819\u201327.","journal-title":"Br J Pharmacol"},{"key":"370_CR41","first-page":"387","volume":"47","author":"H Kuriyama","year":"1995","unstructured":"Kuriyama H, Kitamura K, Nabata H. Pharmacological and physiological significance of ion channels and factors that modulate them in vascular tissues. Pharmacol Rev. 1995;47:387\u2013573.","journal-title":"Pharmacol Rev"},{"key":"370_CR42","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1152\/physrev.1994.74.2.365","volume":"74","author":"TF McDonald","year":"1994","unstructured":"McDonald TF, Pelzer S, Trautwein W, Pelzer DJ. Regulation and modulation of calcium channels in cardiac, skeletal, and smooth muscle cells. Physiol Rev. 1994;74:365\u2013507.","journal-title":"Physiol Rev"},{"key":"370_CR43","doi-asserted-by":"crossref","first-page":"6388","DOI":"10.1073\/pnas.81.20.6388","volume":"81","author":"BP Bean","year":"1984","unstructured":"Bean BP. Nitrendipine block of cardiac calcium channels: high-affinity binding to the inactivated state. Proc Natl Acad Sci U S A. 1984;81:6388\u201392.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"370_CR44","doi-asserted-by":"crossref","DOI":"10.1186\/1472-6793-12-9","volume":"12","author":"P Fransen","year":"2012","unstructured":"Fransen P, Van Hove CE, van Langen J, Schrijvers DM, Martinet W, De Meyer GR, et al. Contribution of transient and sustained calcium influx, and sensitization to depolarization-induced contractions of the intact mouse aorta. BMC Physiol. 2012;12:9.","journal-title":"BMC Physiol"},{"key":"370_CR45","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1038\/nature19102","volume":"537","author":"L Tang","year":"2016","unstructured":"Tang L, Gamal El-Din TM, Swanson TM, Pryde DC, Scheuer T, Zheng N, et al. Structural basis for inhibition of a voltage-gated Ca2+ channel by Ca2+ antagonist drugs. Nature 2016;537:117\u201321.","journal-title":"Nature"},{"key":"370_CR46","doi-asserted-by":"crossref","first-page":"19006","DOI":"10.1074\/jbc.M109.011296","volume":"284","author":"DB Tikhonov","year":"2009","unstructured":"Tikhonov DB, Zhorov BS. Structural model for dihydropyridine binding to L-type calcium channels. J Biol Chem. 2009;284:19006\u201317.","journal-title":"J Biol Chem"},{"key":"370_CR47","first-page":"e2272v1","volume":"4","author":"A Trezza","year":"2016","unstructured":"Trezza A, Bernini A, Spiga O. Identification of \u201con-off residues\u201d in rat CaV1.2 \u03b11C subunit channel using in silico analysis and docking simulation. PeerJ Prepr. 2016;4:e2272v1.","journal-title":"PeerJ Prepr"},{"key":"370_CR48","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/j.bcp.2017.05.020","volume":"140","author":"F Fusi","year":"2017","unstructured":"Fusi F, Trezza A, Spiga O, Sgaragli G, Bova S. Ca(v)1.2 channel current block by the PKA inhibitor H-89 in rat tail artery myocytes via a PKA-independent mechanism: electrophysiological, functional, and molecular docking studies. Biochem Pharmacol. 2017;140:53\u201363.","journal-title":"Biochem Pharmacol"},{"key":"370_CR49","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1038\/sj.bjp.0704877","volume":"137","author":"F Fusi","year":"2002","unstructured":"Fusi F, Saponara S, Sgaragli G, Cargnelli G, Bova S. Ca2+ entry blocking and contractility promoting actions of norbormide in single rat caudal artery myocytes. Br J Pharmacol. 2002;137:323\u20138.","journal-title":"Br J Pharmacol"},{"key":"370_CR50","doi-asserted-by":"crossref","first-page":"C769","DOI":"10.1152\/ajpcell.00529.2004","volume":"288","author":"PH Ratz","year":"2005","unstructured":"Ratz PH, Berg KM, Urban NH, Miner AS. Regulation of smooth muscle calcium sensitivity: KCl as a calcium sensitizing stimulus. Am J Physiol Cell Physiol. 2005;288:C769\u201383.","journal-title":"Am J Physiol Cell Physiol"},{"key":"370_CR51","unstructured":"Pope J, Fenlon D, Thompson A, Shea B, Furst D, Wells G, et al. Ketanserin for Raynaud\u2019s phenomenon in progressive systemic sclerosis. Cochrane Database Syst Rev. 2000;2:CD000954."}],"container-title":["Acta Pharmacologica Sinica"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.nature.com\/articles\/s41401-020-0370-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/s41401-020-0370-1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/s41401-020-0370-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,20]],"date-time":"2023-05-20T21:03:01Z","timestamp":1684616581000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41401-020-0370-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,3,4]]},"references-count":51,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2020,9]]}},"alternative-id":["370"],"URL":"https:\/\/doi.org\/10.1038\/s41401-020-0370-1","relation":{},"ISSN":["1671-4083","1745-7254"],"issn-type":[{"value":"1671-4083","type":"print"},{"value":"1745-7254","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,3,4]]},"assertion":[{"value":"17 October 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 January 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 March 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}